Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:19
|
作者
Caslake, Muriel J. [1 ]
Packard, Chris J.
Robertson, Michele [2 ]
Cooney, Josephine
Nelson, Jeanenne J. [3 ]
Ford, Ian [2 ]
Gaw, Allan [4 ]
Jukema, J. Wouter [5 ]
Macfarlane, Peter W.
Stott, David J.
Shepherd, James
机构
[1] Univ Glasgow, Western Infirm Glasgow, Vasc Biochem Grp, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow G11 6NT, Lanark, Scotland
[3] GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC USA
[4] NHS Greater Glasgow & Clyde, Glasgow Clin Res Facil, Glasgow, Lanark, Scotland
[5] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
关键词
Lipoprotein-associated phospholipids A(2); Elderly; Prosper; Inflammatory markers; Coronary heart disease risk; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; ATHEROSCLEROSIS RISK; ISCHEMIC-STROKE; PREDICTION; EVENTS; MARKERS; WOMEN;
D O I
10.1016/j.atherosclerosis.2009.10.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory biomarker that circulates mainly bound to LDL. We evaluated the association of Lp-PLA(2) with vascular events in the elderly where the importance of LDL is diminished as a risk factor for coronary disease. Methods: Mass and activity of Lp-PLA(2) were related to risk over 3.2 years for vascular events (definite or suspected death from CHD, non-fatal MI, fatal or non-fatal stroke) in the 2804 men and 3000 women age 70-82 years in the Prospective Study of Pravastatin in the Elderly (PROSPER). Results: Lp-PLA(2) showed a moderate, positive association with risk of a vascular event with hazard ratios of 1.25 (confidence interval (CI) 1.02-1.54) for mass and 1.39 (CI 1.14-1.70) for activity for top versus bottom quartile. Risk associations were attenuated when classical risk factors, lipids and in. ammatory markers - C-reactive protein and white cell count - were included in the models. Lp-PLA(2) was unrelated to stroke risk. Inclusion of all three in. ammatory markers in multivariate models negated the association of HDL cholesterol with risk (hazard ratio 0.98; CI 0.88-1.10) and increased prediction of coronary events; the C statistic rose from 63.2% to 64.4% (P < 0.001). Conclusion: In elderly people Lp-PLA(2), alongside other inflammatory indices, is a potential biomarker for vascular events, particularly CHD. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [21] Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease
    Hu, Yun
    Li, Ting-ting
    Zhou, Wei
    Lu, Ting-ting
    Li, Feng-fei
    Ding, Bo
    Liu, Bing-li
    Xie, Xiao-jing
    Ma, Jian-hua
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 194 - 201
  • [22] Lipoprotein-Associated Phospholipase A2 as a Risk of Coronary Disease in Statin User
    Chung, Hyemoon
    Kim, Myung-Hyun
    Lee, Byoung Kwon
    Kwon, Hyuek Moon
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (07): : 39S - 39S
  • [23] Predicting the Risk of Cardiovascular DiseaseWhere Does Lipoprotein-Associated Phospholipase A2 Fit In?
    Natalie Khuseyinova
    Wolfgang Koenig
    Molecular Diagnosis & Therapy, 2007, 11 : 203 - 217
  • [24] Lipoprotein-associated phospholipase A2 and cardiovascular risk -: State of the evidence and future directions
    Iribarren, C
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (01) : 5 - 6
  • [25] Lipoprotein-associated phospholipase A2 and cardiovascular events in high risk coronary artery disease patients
    Maiolino, G.
    Pedon, L. P.
    Cesari, M. C.
    Frigo, A. C.
    Barisa, M.
    Rossitto, G.
    Pagliani, L.
    Seccia, T. M.
    Zanchetta, M.
    Paolo, G. P.
    EUROPEAN HEART JOURNAL, 2012, 33 : 1076 - 1076
  • [26] Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target
    Ali, Muzammil
    Madjid, Mohammad
    FUTURE CARDIOLOGY, 2009, 5 (02) : 159 - 173
  • [27] Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease A Systematic Review of the Literature
    Madjid, Mohammad
    Ali, Muzammil
    Willerson, James T.
    TEXAS HEART INSTITUTE JOURNAL, 2010, 37 (01): : 25 - 39
  • [28] Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation
    Chen, Jialing
    Zhang, Huisheng
    Chen, Wenwen
    CLINICA CHIMICA ACTA, 2019, 488 : 143 - 149
  • [29] An evolving story of lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction
    Macphee, CH
    Nelson, JJ
    EUROPEAN HEART JOURNAL, 2005, 26 (02) : 107 - 109
  • [30] Blood Pressure Variability and Cardiovascular Risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Poortvliet, Rosalinde K. E.
    Ford, Ian
    Lloyd, Suzanne M.
    Sattar, Naveed
    Mooijaart, Simon P.
    de Craen, Anton J. M.
    Westendorp, Rudi G. J.
    Jukema, J. Wouter
    Packard, Christopher J.
    Gussekloo, Jacobijn
    de Ruijter, Wouter
    Stott, David J.
    PLOS ONE, 2012, 7 (12):